I'm delighted to share exciting news about a transformational move in our international growth strategy. Microba is taking a leading position in microbiome testing in the United Kingdom through the acquisition of Invivo Clinical, a leader in delivering microbiome testing to healthcare professionals in the UK. Together with our major strategic partner, Sonic Healthcare, the Invivo acquisition provides us with deep access to the entire UK healthcare market, spanning both private practice and the public NHS environment. The UK is a key market for us, with an estimated 49,000 healthcare professionals positioned to employ Microba's testing technology into their practice. This acquisition of Invivo provides us with an active customer base of over 1,700 healthcare professionals, a geographical footprint and laboratory in the UK, and an experienced and well-credentialed team that understand the UK market intimately. The synergies to be unlocked between Invivo and Microba provide multiple growth opportunities. Firstly, Invivo providing our advanced MetaXplore testing to their customer base. Together, we expect Microba's world-leading MetaXplore test will become the most favored microbiome test for healthcare professionals in the UK. And secondly, taking Invivo's test range, spanning oral, vaginal, and urinary microbiome testing beyond the UK through the Microba partner distribution network. We see microbiome testing and therapeutics becoming a routine part of healthcare, and Microba is in position at the forefront of this market. The acquisition of Invivo completes a key next step in our strategy to become the dominant global leader in microbiome testing in healthcare. All of this delivers on the company's international testing growth strategy with a targeted and highly synergistic acquisition, and delivers on our commitment to advance human health through precision microbiome science.